

Res. Asst. Yaşa Gül MUTLU

Personal Information

Email: ygmumlu@medipol.edu.tr

Web: <https://avesis.medipol.edu.tr/ygmumlu>

Education Information

Expertise In Medicine, Dokuz Eylul University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2015 - 2019

Undergraduate, Hatay Mustafa Kemal University, Tayfur Ata Sökmen Tıp Fakültesi, Tayfur Ata Sökmen Tıp Pr., Turkey 2008 - 2014

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience**
Yiğit Kaya S., MUTLU Y. G., MALKAN Ü. Y., MEHTAP Ö., Keklik Karadağ F., Korkmaz G., ELVERDİ T., Saydam G., Özet G., AR M. C., et al.
LEUKEMIA RESEARCH, vol.140, 2024 (SCI-Expanded)
- II. **Predicting the CD34 content of mobilized peripheral blood leukapheresis products: single institution experience over 20 years**
MUTLU Y. G., Sevcik J., Kiss J. E., Lister J., Moore L. R., Donnenberg A. D.
Cytotherapy, vol.26, no.2, pp.171-177, 2024 (SCI-Expanded)
- III. **Germline CEBPA Mutation as a Rare Cause of Chronic Neutropenia**
Askin A. E., Bektas S., Serin I., MUTLU Y. G., Aydın B. B., SEVİNDİK Ö. G.
Indian Journal of Hematology and Blood Transfusion, 2024 (SCI-Expanded)
- IV. **Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?**
Serin I., SEVİNDİK Ö. G., Balık Aydın B., MELEK E., MUTLU Y. G., BİLGİN H., Bekoz H., KAYNAR L.
TRANSFUSION AND APHERESIS SCIENCE, vol.62, no.6, 2023 (SCI-Expanded)
- V. **Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case**
Mutlu Y. G., Yiğit Kaya S., Maral S., Melek E., Başlar Z., Kaynar L., Sevindik Ö. G.
FRONTIERS IN IMMUNOLOGY, vol.14, 2023 (SCI-Expanded)
- VI. **Intravascular B-cell lymphoma with generalized telangiectasias**
Erol V. B., MUTLU Y. G., Balık B., MERT A., Mergen S., Mergen M., Serin I., ÇAKIR A., ÖZDEN F., SEVİNDİK Ö. G.
JDDG - Journal of the German Society of Dermatology, vol.21, no.9, pp.1025-1027, 2023 (SCI-Expanded)
- VII. **Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient**
Yiğit Kaya S., Bektas S., Askin A. E., Balık Aydın B., MUTLU Y. G., SEVİNDİK Ö. G.
Annals of Hematology, vol.102, no.6, pp.1599-1600, 2023 (SCI-Expanded)
- VIII. **Prognostic Factors and Intensive Care Outcome in Post-Transplant Phase of Hematopoietic Stem Cell Transplantation: Intensive Care Outcome in Hematopoietic Stem Cell Transplantation**
MUTLU Y. G., Aydın B. B., ERDOĞAN C., KIZILASLAN D., BEKÖZ H. S., Gemici A., KAYNAR L., SEVİNDİK Ö. G.
Indian Journal of Hematology and Blood Transfusion, vol.39, no.2, pp.167-172, 2023 (SCI-Expanded)
- IX. **To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of**

hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission

SEVİNDİK Ö. G., Mergen M., Mergen S., MUTLU Y. G., Aydın B. B., Serin I.

Annals of Hematology, vol.101, no.11, pp.2545-2547, 2022 (SCI-Expanded)

- X. **Persistent polyclonal b-cell lymphocytosis with binucleated lymphocytes Çift çekirdekli lenfositler ile karakterize, kalıcı poliklonal b-hücreli lenfositoz**

Aydın B. B., MUTLU Y. G., SEVİNDİK Ö. G.

Turkish Journal of Hematology, vol.38, no.2, pp.173-174, 2021 (SCI-Expanded)

Articles Published in Other Journals

- I. **Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers**
Sadri S., Yonal-Hindilerden I., mutlu Y. g., tiryaki t. o., Gemici A., Beköz H. S., Sevindik O. G., Hindilerden F., Kalayoglu Besisik S., Nalcaci M., et al.
The European Research Journal, vol.9, no.6, pp.1368-1379, 2023 (Peer-Reviewed Journal)
- II. **Should Core Needle Lymph Node Biopsy be a Relevant Alternative to Surgical Excisional Biopsy in Diagnostic Work Up of Lymphomas?**
MUTLU Y. G., BALIK B., ÇAKIR A., CANÖZ Ö., EROL C., SEVİNDİK Ö.
Eurasian Journal of Medicine, vol.55, no.2, pp.114-119, 2023 (ESCI)
- III. **First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS)**
SEVİNDİK Ö. G., MUTLU Y. G., Aydın B. B., Serin I.
HemaSphere, vol.6, no.7, 2022 (Scopus)
- IV. **Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing and clinical implications**
MUTLU Y. G., BALIK B., AYAZ A., SECA F., SEVİNDİK Ö.
Annals of Medical Research, vol.29, no.4, pp.406-411, 2022 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **Chapter 23: Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease**
KAYNAR L., MUTLU Y. G.
in: Problem Solving in Apheresis Medicine, İlknur KOZANOĞLU, Editor, Springer Nature Switzerland AG, pp.1-14, 2023

Refereed Congress / Symposium Publications in Proceedings

- I. **SANTRAL SİNİR SİSTEMİ TUTULUMU (SSS) İLE SEYREDEN BİR MULTİPL MYELOM HASTASINDA ELRANATAMAB İLE ELDE EDİLEN YÜZ GÜLDÜRÜCÜ YANIT**
MUTLU Y. G., YİĞİT KAYA S., MARAL S., MELEK E., BAŞLAR Z., KAYNAR L., SEVİNDİK Ö. G.
49.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 November 2023
- II. **MULTIPLE MYELOM HASTALARININ MOBİLİZASYONUNDA JENERİK PLERİXAFOR İLE ORİJİNAL PLERİXAFORUN ETKİNLİK VE GÜVENLİĞİNİN KARŞILAŞTIRILMASI: ÇOK MERKEZLİ ÇALIŞMA**
YİĞİT KAYA S., MUTLU Y. G., YÜCEL O. K., ÖZEN İ. N., ATAŞ Ü., MELEK E., MARAL S., KARAKUŞ V., KAYNAR L., SEVİNDİK Ö. G.
49. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 November 2023

- III. **YÜKSEK DOZ METOTREKSATIN BAŞARISIZ OLDUĞU SEKONDER SSS LENFOMA OLGUSUNDA TEDDİR İLE TRANSPLANTASYONA BAŞARILI BİR KÖPRÜ TEDAVİ**
YİĞİT KAYA S., MELEK E., MUTLU Y. G., BEKÖZ H. S., MARAL S., KAYNAR L., SEVİNDİK Ö. G.
49.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 November 2023
- IV. **PLERIXAFOR IN AUTOLOGOUS STEM CELL TRANSPLANTATION: DOES IT AFFECT ENGRAFTMENT KINETICS?**
SERİN İ., SEVİNDİK Ö. G., BALIK AYDIN B., MELEK E., MUTLU Y. G., BİLGİN H., BEKÖZ H. S., KAYNAR L.
49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Paris, France, 23 - 26 April 2023, pp.378-379
- V. **IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia**
SEVİNDİK Ö. G., GEMİCİ A., MUTLU Y. G., BALIK AYDIN B., ÇAKIR A.
Society of Hematologic Oncology Eighth Annual Meeting, Houston, United States Of America, 9 - 12 September 2020